Form 4: Zymeworks CEO Galbraith's Equity Transactions

Zymeworks Inc. CEO Kenneth Galbraith reported significant equity transactions, including RSU vesting, stock option grants, and a non-discretionary 'sell-to-cover' sale.

Summary

• Kenneth Galbraith, Chair & CEO of Zymeworks Inc. (ZYME), reported multiple equity transactions on January 12, 2026.
• Acquired 64,000 shares of common stock upon the vesting of restricted stock units (RSUs) granted on January 10, 2025, at a price of $0.00.
• Disposed of 30,424 shares of common stock at a weighted average price of $22.6735 to cover tax withholding obligations and other fees, which was a mandatory 'sell to cover' transaction.
• Beneficial ownership of common stock following these transactions is 226,842 shares.
• Received a grant of 216,000 stock options with an exercise price of $23.16, expiring on January 11, 2036.
• Received a grant of 144,000 restricted stock units (RSUs).
• Received a grant of 222,000 performance stock units (PSUs), representing the maximum number that may be earned based on cumulative total shareholder return (TSR) goals over a three-year period ending January 12, 2029.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing detailing executive compensation and a mandatory tax-related stock sale. It does not contain information that would significantly alter the company's fundamental outlook or market sentiment, hence a neutral score.

Positives

• Increased equity holdings for the CEO through RSU vesting and new grants of stock options, RSUs, and PSUs, aligning management interests with shareholders.
• The grant of performance stock units (PSUs) ties a significant portion of executive compensation directly to the company's total shareholder return (TSR) performance over a three-year period.
• The stock options have a long expiration date (January 11, 2036), providing a long-term incentive for value creation.

Negatives

• A portion of vested shares (30,424) was sold, though this was a non-discretionary 'sell to cover' for tax obligations, not a voluntary sale.

Risks

• Performance Stock Units (PSUs) are contingent on achieving specific cumulative total shareholder return (TSR) goals over a three-year period ending January 12, 2029, meaning the actual number of shares received could be lower than the maximum reported (222,000) or zero.
• Vesting of PSUs and other equity awards is generally contingent on the reporting person's continued service to the company, with limited exceptions for termination without cause or change of control.

Future Outlook

The reporting person has significant future equity vesting events tied to continued service and, for Performance Stock Units, achievement of specific Total Shareholder Return (TSR) goals over a three-year period ending January 12, 2029. Stock options granted have a long-term expiration date of January 11, 2036, indicating a long-term incentive structure.

Industry Context

The reported equity transactions are typical for executive compensation in the biotechnology industry, where a significant portion of remuneration is often tied to stock-based incentives to align management's interests with long-term shareholder value creation. The use of RSUs, PSUs, and stock options is a standard practice to attract and retain executive talent in a competitive sector like biotech.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs, PSUs, and stock options, is consistent with common practices observed in other publicly traded biotechnology companies.
• The vesting schedules (e.g., three to four equal annual installments for RSUs, 25% on first anniversary then monthly for options) are standard for executive incentive plans.
• Performance-based units (PSUs) tied to Total Shareholder Return (TSR) goals are a common mechanism to link executive pay directly to company performance relative to peers or market indices, such as the Nasdaq Biotech Index mentioned.

Stakeholder Impact

• Shareholders: The equity grants, particularly PSUs tied to TSR, aim to align the CEO's incentives with shareholder value creation. The 'sell to cover' transaction is a routine event and not a discretionary sale.
• Employees: No direct impact on general employees mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of Restricted Stock Units (RSUs) and stock options according to their respective schedules.
• Evaluation of cumulative Total Shareholder Return (TSR) goals for Performance Stock Units (PSUs) over the three-year performance period ending January 12, 2029.
• Board of directors' certification of PSU achievement at the end of the performance period.

Key Dates

Keywords

Zymeworks, ZYME, Form 4, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Grant, CEO, Kenneth Galbraith, Biotech